Search
Mebendazole
go.drugbank.com/drugs/DB00643ApprovedInvestigationalVet approvedA benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem]
QS-21
go.drugbank.com/drugs/DB05400InvestigationalAs a vaccine additive, it is currently being evaluated in clinical trials in a variety of disease areas by Antigenics. … QS-21 is an investigational adjuvant, which is a substance added to vaccines and other immunotherapies that is designed to enhance the body’s immune response to the antigen contained within the treatment
Calcitonin gene-related peptide
go.drugbank.com/drugs/DB06379InvestigationalIn particular, it is a potent endogenous vasodilator. … As a potential drug, it has demonstrated in preclinical studies a profile that could make it an ideal anti-asthmatic drug candidate with bronchodilatory, bronchoprotecting and anti-inflammatory properties
Foretinib
go.drugbank.com/drugs/DB12307InvestigationalForetinib is an orally available small molecule compound designed to target multiple RTKs implicated in the development, progression and spread of cancer. … Foretinib has been used in trials studying the treatment of Cancer, Breast Cancer, Carcinoma, Renal Cell, Recurrent Breast Cancer, and Neoplasms, Head and Neck, among others.
ICX-RHY
go.drugbank.com/drugs/DB05716ExperimentalThe drug was under investigation in clinical trials in the UK for the treatment of skin erosions in recessive dystrophic epidermolysis bulllosa. … ICX-RHY is an investigational therapy comprised of cultured allogeneic fibroblasts.
Iolopride I-123
go.drugbank.com/drugs/DB20028ExperimentalThe usage of the INN stem '-pride' in the name indicates that Iolopride I-123 is a sulpiride derivative and analogue. Iolopride I-123 has a monoisotopic molecular weight of 400.06 Da.
Categories: Compounds used in a research, industrial, or household settingBelnacasan
go.drugbank.com/drugs/DB05507InvestigationalVX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.
PF-03187207
go.drugbank.com/drugs/DB05746InvestigationalBased on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP. … The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount of fluid in the eye, is believed to be one of the principal causes of glaucoma.